Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna questioned on Trump, RFK Jr. impact on vaccine work
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
FierceBiotech5h
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
FiercePharma10d
Moderna slammed over social media posts ‘inappropriately directed’ at kids
A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
BGR1mon
Moderna CEO says that we’re going to be living with COVID-19 ‘forever’
Vaccines like the Pfizer/BioNTech and Moderna drugs that are already in use, and the other candidates that are still in testing, could help countries reach herd immunity faster and safer than ...
Yahoo Finance24d
Where Will Moderna Be in 3 Years?
Separately, Moderna's drugs with somewhat more niche applications could drive the stock's price higher even in advance of their approval.
2 Biotech Stocks to Buy Hand Over Fist in February
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...